Retatrutide
Research Peptide
A novel 39-amino acid peptide targeting GLP-1, GIP, and glucagon receptors. Currently in Phase 3 clinical trials by Eli Lilly.
Mechanism of Action
Retatrutide simultaneously activates three incretin hormone receptors, creating a synergistic effect studied in metabolic research applications.
GIP Receptor
GIPRHighest affinity binding - glucose-dependent insulin secretion and lipid metabolism
GLP-1 Receptor
GLP-1RSatiety signaling, gastric emptying modulation, glycemic control
Glucagon Receptor
GCGRHepatic glucose regulation, thermogenesis, lipid mobilization
EC50 values represent the concentration required for 50% maximal response. Lower values indicate higher binding affinity. Data sourced from published research literature.
Research Highlights
Key findings from published Phase 2 clinical trials and peer-reviewed research.
Published Research Citations
Data presented is derived from peer-reviewed publications including the New England Journal of Medicine, Nature Medicine, and PubMed Central. Research outcomes are for informational purposes only and pertain to clinical trial contexts. This compound is sold strictly for laboratory research purposes.
Molecular Profile
Retatrutide (LY3437943) is a weekly single-agent peptide featuring strategic amino acid modifications for enhanced stability and receptor selectivity.
Available for Research
High-purity Retatrutide peptide for qualified research applications. Third-party tested and verified.
Research starter quantity
Standard research quantity
Try instead:
RT 10MG or RT 30MG available
Extended research supply
Secure checkout with multiple payment options available
Certificate of Analysis
Every batch is third-party tested for purity and identity. View our HPLC test results confirming 99%+ purity.
RT 10MG - COA
HPLC Purity Analysis
RT 20MG - COA
HPLC Purity Analysis
Certificates of Analysis are included with every order. Additional testing documentation available upon request.
FOR RESEARCH PURPOSES ONLY
This product is intended strictly for laboratory and scientific research purposes. It is not intended for human or animal consumption, therapeutic use, or any other non-research application.
Retatrutide (LY3437943) is an investigational compound currently undergoing clinical trials. It has not been approved by the FDA or any other regulatory agency for medical use.
By purchasing this product, you confirm that you are at least 21 years of age, are purchasing for legitimate research purposes, and agree to our Terms & Conditions.
No Medical Claims
Premier Research makes no claims regarding the safety, efficacy, or therapeutic benefits of this compound. All research data presented is sourced from published clinical literature and is for informational purposes only.
Qualified Researchers
This product is sold exclusively to qualified researchers and institutions. Purchasers must have appropriate knowledge and facilities for handling research chemicals safely and responsibly.
Ready to Begin Your Research?
High-purity Retatrutide peptide available for qualified research applications. Order today for fast USA shipping.